J. Santella

发表

MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products.

J. Wityak, G. Trainor, F. Hobbs, 1998, Bioorganic & medicinal chemistry letters.

Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.

W. Price, J. Duncia, J. Santella, 1991, Journal of medicinal chemistry.

Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.

G. Trainor, M. Covington, C. Decicco, 2005, Journal of medicinal chemistry.

DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors.

T. Olah, L. Cornelius, J. Santella, 2010, Bioanalysis.

Biaryl substituted alkylboronate esters as thrombin inhibitors

J. Wityak, P. Weber, C. Dominguez, 1997 .

The discovery of BMS-457, a potent and selective CCR1 antagonist.

W. Guo, C. Cavallaro, A. Tebben, 2013, Bioorganic & medicinal chemistry letters.

Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.

J. Barrish, C. Cavallaro, A. Tebben, 2014, Journal of medicinal chemistry.

Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.

Michael G. Yang, S. Mandlekar, A. Mathur, 2021, ACS medicinal chemistry letters.

Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity

K. McIntyre, Wen-pin Yang, S. Ruepp, 2017, The Journal of Immunology.

This information is current as Demonstrates Steroid Sparing Activity Disease in Murine Lupus Models and Selective IRAK 4 Inhibition Attenuates

K. McIntyre, Wen-pin Yang, S. Ruepp, 2016 .

CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.

G. Trainor, M. Covington, C. Decicco, 2002, Bioorganic & medicinal chemistry letters.

Assessing the risk of drug crystallization in vivo.

E. Janovitz, D. Drexler, S. Ruepp, 2019, Journal of pharmacological and toxicological methods.

N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.

J. Trzăskos, C. Decicco, P. Carter, 2005, Bioorganic & medicinal chemistry letters.

Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.

G. Trainor, M. Covington, C. Decicco, 2004, Bioorganic & medicinal chemistry letters.

Balanced angiotensin II receptor antagonists. III. The effects of substitution at the imidazole 5-position.

P. Timmermans, J. Duncia, J. Santella, 1994 .

Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling.

J. Tokarski, D. Xie, N. Araníbar, 2017, MedChemComm.

Three synthetic routes to a sterically hindered tetrazole. A new one-step mild conversion of an amide into a tetrazole

J. Duncia, J. Santella, M. Pierce, 1991 .

Development of a Scalable Synthesis for the Potent Kinase Inhibitor BMS-986236; 1-(5-(4-(3-Hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-4-(isopropylamino)pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile

A. Mathur, A. Gupta, P. Carter, 2019, Organic Process Research & Development.

gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.

Michael G. Yang, J. Barrish, S. Mandlekar, 2010, Bioorganic & medicinal chemistry letters.

Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).

Michael G. Yang, J. Barrish, A. Tebben, 2012, Bioorganic & medicinal chemistry letters.

Pyrazoles, 1,2,4-triazoles, and tetrazoles as surrogates for cis-amide bonds in boronate ester thrombin inhibitors.

P. Weber, R. Knabb, R. Alexander, 1998, Bioorganic & Medicinal Chemistry Letters.

Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5.

D. J. Nelson, J. Barrish, S. Mandlekar, 2015, ACS medicinal chemistry letters.

Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.

G. Trainor, M. Covington, C. Decicco, 2004, Bioorganic & medicinal chemistry letters.

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.

I. Kariv, S. Mandlekar, A. Tebben, 2008, Bioorganic & medicinal chemistry letters.

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.

A. Tebben, P. Carter, J. Duncia, 2008, Bioorganic & medicinal chemistry letters.

Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors.

J. Wityak, G. Trainor, R. Copeland, 2004, Bioorganic & medicinal chemistry letters.

Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672.

Michael G. Yang, Michael A. Galella, J. Barrish, 2019, ACS medicinal chemistry letters.

EXP597, a nonpeptide angiotensin II receptor antagonist with high affinities for the angiotensin AT1 and AT2 receptor subtypes.

P. Timmermans, J. Duncia, J. Santella, 1994, European journal of pharmacology.

Development and implementation of a stereoselective normal-phase liquid chromatography-tandem mass spectrometry method for the determination of intrinsic metabolic clearance in human liver microsomes.

A. Tymiak, J. Santella, C. D’arienzo, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.